Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol

Cellular and Molecular Neurobiology

Volumn 17, Issue 2, 1997, Pages 227-233

  Fang, Jian ^a   Baker, Glen B ^a   Silverstone, Peter H ^a   Coutts, Ronald T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cytochrome P450; drug metabolism; drug drug interactions; haloperidol; isoenzyme

Indexed keywords

CYTOCHROME P450; FLUOXETINE; HALOPERIDOL;

ARTICLE; DEALKYLATION; DRUG METABOLISM; ENZYME ANALYSIS; ENZYME METABOLISM; EXTRAPYRAMIDAL SYMPTOM; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER MICROSOME; MICROSOME; MOTOR DYSFUNCTION; OXIDATION; PRIORITY JOURNAL;

EID: 0030930935     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026317929335     Document Type: Article

References (15)

1. Daniel, D. G., Randolph, C., Jaskiw, G., Handel, S., Williams, T., Abi-Dargham, A., Shoaf, S., Egan, M., Elkashef, A., Liboff, S., and Linnoila, M. (1994). Coadministration of fluvoxamine increases serum concentrations of haloperidol. J. Clin. Psychopharmacol., 14:340-343.
2. Fang, J., and Gorrod, J. W. (1991). Dehydration is the first step in the biotransformation of haloperidol to its pyridinium metabolite. Toxicol. Lett. 59:117-123.
3. Fang, J., and Gorrod, J. W. (1993). An HPLC system for the analysis of haloperidol and seven of its metabolites in microsomal preparations. J. Chromatogr. 614:267-273.
4. +) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology 121:373-378.
5. Fang, J., Baker, G. B., and Coutts, R. T. (1996). Determination of 4-chlorophehyl-4-hydroxypiperidine, a metabolite of haloperidol, by gas chromatogrpahy with electron-capture detection. J. Chromatogr. Biomed. Appl. 682:283-288.
6. Forsman, A., and Larsson, M. (1978). Metabolism of haloperidol. Curr. Ther. Res. 24:567-568.
7. Goff, D. C., Midha, K. K., Brotman, A. W., Waites, M., and Baldessarini, R. J. (1991). Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am. J. Psychiatry 148:790-792.
8. Gorrod, J. W., and Fang, J. (1993). On the metabolism of haloperidol. Xenobiotica 23:459-508.
9. LLerena, A., Aim, C., Dahl, M-.L., Ekqvist, B., and Bertilsson, L. (1992). Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug Monit. 14:92-97.
10. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 268:380-387.
11. Soudijn, W., Van Wijngaarden, I., and Allewijn, F. (1967). Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. I. Excretion and metabolism of haloperidol and nine related butyrophenone-derivatives in the Wistar rat. Eur. J. Pharmacol. 1:47-57.
12. Subramanyam, B., Rollema, H., Woolf, T., and Castagnoli, N., Jr. (1990). Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem. Biophys. Res. Commun. 166:238-244.
13. Tate, J. L. (1989). Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am. J. Psychiatry 146:399-400.
14. Tyndale, R. F., Kalow, W., and Inaba, T. (1991). Oxidation of reduced haloperidol to haloperidol: Involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br. J. Clin. Pharmacol. 31:655-660.
15. Young, D., Midha, K. K., Fossler, M. J., Hawes, E. M., Hubbard, J. W., McKay, G., and Korchinski, E. D. (1993). Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: Implications for the involvement of cytochrome P450IID6. Eur. J. Clin. Pharmacol. 44:433-438.